Organization Profile

You just read:

Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years

News provided by

Genzyme

Apr 27, 2015, 13:11 ET